Personalis Inc Revenue Growth Rates (PSNL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Personalis Inc   (NASDAQ: PSNL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

PSNL's Revenue Growth by Quarter and Year

Personalis Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PSNL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 22.36
1st Quarter March 15.47
FY 37.83

PSNLs Annual Revenue
Personalis Inc 's Revenue in the fiscal year 2025 $ 69.65 millions
Personalis Inc 's Revenue in the fiscal year 2024 $ 84.61 millions
Personalis Inc 's Revenue in the fiscal year 2023 $ 73.48 millions
Personalis Inc 's Revenue in the fiscal year 2022 $ 65.05 millions
Personalis Inc 's Revenue in the fiscal year 2021 $ 85.49 millions




PSNL Revenue second quarter 2026 Y/Y Growth Comment
Personalis Inc reported Revenue improvement of 29.98% year on year in the second quarter 2026, to $ 22.36 millions, this is lower than Personalis Inc 's recent average Revenue improvement of 37.15%.

Looking into second quarter 2026 results within Medical Laboratories industry 22 other companies have achieved higher Revenue growth. While Personalis Inc ' s Revenue rise of 29.98% ranks overall at the positon no. 2342 in the second quarter 2026.


PSNL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 3.27 % -14.63 % 17.7 %
3rd Quarter September - -43.6 % 40.88 % 22.81 %
2nd Quarter June 29.98 % -23.83 % 35.21 % -8.44 %
1st Quarter March -24.94 % 5.53 % 3.55 % 23.83 %
FY   - -17.68 % 15.14 % -

Financial Statements
Personalis Inc 's second quarter 2026 Revenue $ 22.36 millions PSNL's Income Statement
Personalis Inc 's second quarter 2025 Revenue $ 17.20 millions Quarterly PSNL's Income Statement


PSNL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 19.66 % -34.66 % 7.84 %
3rd Quarter September - -15.7 % 13.86 % 9.28 %
2nd Quarter June 44.52 % -16.55 % 15.62 % -11.45 %
1st Quarter March -10.84 % 22.68 % -0.76 % 12.8 %
FY (Year on Year)   - -17.68 % 15.14 % -


Back to PSNL Growth rate Comparisons >> Back to PSNL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #341
Overall #2342

Revenue Y/Y Growth Statistics
High Average Low
319.44 % 37.15 % -24.71 %
(Mar 31 2021)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #23
Healthcare Sector #341
Overall #2342
Revenue Y/Y Growth Statistics
High Average Low
319.44 % 37.15 % -24.71 %
(Mar 31 2021)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Personalis Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
111.31 % 7.62 % -34.65 %
(Jun 30 2018)  


PSNL's II. Quarter Q/Q Revenue Comment
Personalis Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 44.52%, to $ 22.36 millions, from $15.47 millions in the first quarter.
PSNL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While Personalis Inc 's Revenue growth quarter on quarter, overall rank is 293.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #75
Overall #293
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #2
Healthcare Sector #75
Overall #293
Revenue Q/Q Growth Statistics
High Average Low
111.31 % 7.62 % -34.65 %
(Jun 30 2018)  


PSNL's II. Quarter Q/Q Revenue Comment
Personalis Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 44.52%, to $ 22.36 millions, from $15.47 millions in the first quarter.
PSNL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry only one company achieved higher sequential Revenue growth. While Personalis Inc 's Revenue growth quarter on quarter, overall rank is 293.


Personalis Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 69.67 $ 64.52 $ 69.65 $ 69.10 $ 80.32
Y / Y Revenue Growth (TTM) -13.26 % -24.71 % -17.69 % -21.02 % 0.36 %
Year on Year Revenue Growth Overall Ranking # 2584 # 967 # 609 # 509 # 365
Seqeuential Revenue Change (TTM) 7.99 % -7.37 % 0.79 % -13.96 % -6.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 3044 # 2310 # 1992 # 1224 # 860


Cumulative Revenue growth Comment
Personalis Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Personalis Inc 's annual Revenue decline would be -13.26% year on year to $70 millions.

In the Healthcare sector 372 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 967 to 2584.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 373
Overall # 2584

Revenue TTM Y/Y Growth Statistics
High Average Low
72.62 %
 7.13 %
-24.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 417
S&P 500 # 3044
Cumulative Revenue growth Comment
Personalis Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Personalis Inc 's annual Revenue fall would be -13.26% year on year to $70 millions.

In the Healthcare sector 372 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 967 to 2584.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 373
Overall # 2584

Revenue TTM Y/Y Growth Statistics
High Average Low
72.62 %
7.13 %
-24.71 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 417
S&P 500 # 3044




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PSNL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions


About Personalis Inc Revenue Growth Rates (PSNL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Personalis Inc (CIK 1527753).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-332817
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Personalis Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.